An Immersive PARP inhibitor Algorithm: Improving Clinical Outcomes Through PARP Inhibition in Patients with Advanced Ovarian Cancer
November 5, 2020
November 5, 2021
Scroll to the Bottom of this Information to Begin this Course
Provided by Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from GlaxoSmithKline.
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™
- Nurses — 1.25 Nursing Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for medical oncologists, gynecologist oncologists, surgical oncologists, oncology nurses and other healthcare providers who care for patients with ovarian cancer, including physician assistants and nurse practitioners.
This digital algorithm offers stepwise practical guidance to prepare oncologists to employ PARP inhibitors effectively and safely in eligible ovarian cancer patients. Due to the many patient characteristics that determine eligibility, the algorithm supports branching logic in the context of patient disease status, response to chemotherapy, molecular profile, and tolerability.
Upon completion of this activity, participants will be able to:
- Discuss strategies for identifying appropriate patients for implementation of PARP inhibitors in advanced ovarian cancer
- Review clinical data on the safety, efficacy, and tolerability of PARP inhibitors in the maintenance and disease recurrence setting following platinum-based chemotherapy
- Identify adverse events related to PARP inhibitors and outline potential strategies for management
Summer B. Dewdney, MD
Assistant Professor, Gynecologic Oncology
Division of Obstetrics & Gynecology
Rush University Medical Center
Bradley Monk, MD, FACOG, FACS
Medical Director, Gynecologic Oncology Research
Arizona Oncology, US Oncology Network
Professor, Gynecologic Oncology
Arizona College of Medicine – Phoenix
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this internet enduring material activity for a maximum of one and a quarter (1.25) AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this internet enduring material activity for a maximum of one and a quarter (1.25) nursing contact hour(s).
Disclosures of Conflicts of Interest
As a provider of continuing education, Rush University Medical Center asks everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
The faculty provided the following relevant financial relationships:
Summer B. Dewdney, MD
- Consultant: AstraZeneca
Bradley Monk, MD, FACOG, FACS
- Consultant: AbbVie, Advaxis, Agenus, Akeso Bio, Amgen, Aravive, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical, ChemoID, Clovis, Dicepheria, Eisai, Geistlich, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Immunomedics, Incyte, Iovance, Laekna Health Care, Merck, Mersana, Myriad, Nucana, Oncomed, Oncoquest, Oncosec, Perthera, Pfizer, Puma, Regeneron, Roche/Genentech, Senti Biosciences, Starton Therapeutics (formerly Chemiocare), Takeda, Tarveda, TESARO/GlaxoSmithKline, Vavotar Life Sciences, VBL, Vigeo
- Speakers Bureau: AstraZeneca, Clovis, Eisai, Merck, Roche/Genentech, TESARO/GlaxoSmithKline
The remaining planners and reviewers of this activity have no relevant financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
For CME questions please contact Katlyn Cooper at email@example.com